Nanoviricides (NNVC) Share-based Compensation Growth (3y) (2017 - 2026)
Nanoviricides (NNVC) Share-based Compensation Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.49% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.55% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 7.39% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30.98% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -51.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.60% |
| Dec 31, 2025 | -65.51% |
| Sep 30, 2025 | 56.58% |
| Jun 30, 2025 | -19.75% |
| Mar 31, 2025 | -49.15% |
| Dec 31, 2024 | -66.73% |
| Sep 30, 2024 | 2.89% |
| Jun 30, 2024 | -3.07% |
| Mar 31, 2024 | 14.56% |
| Dec 31, 2023 | 12.31% |
| Sep 30, 2023 | 17.37% |
| Jun 30, 2023 | -48.28% |
| Mar 31, 2023 | 55.47% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -36.02% |
| Mar 31, 2022 | 79.43% |
| Dec 31, 2021 | 55.13% |
| Sep 30, 2021 | -21.54% |
| Dec 31, 2020 | 39.35% |